Form 8-K June 18, 2012
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event) June 18, 2012; (June 15, 2012)
GUIDED THERAPEUTICS, INC.

GUIDED THERAPEUTICS INC

Delaware 0-22179 58-2029543

(Exact Name of Registrant as Specified in Its Charter)

(State or Other Jurisdiction of (Commission File Number) (IRS Employer Identification No.) Incorporation)			
5835 Peachtree Corners East, Suite D 30092 Norcross, Georgia (Zip Code) (Address of Principal Executive Offices)			
Registrant's Telephone Number, Including Area Code: (770) 242-8723			
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:			
£Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)			
£Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)			
£Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))			
£Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))			
1			

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 15, 2012, the Company held its annual meeting of stockholders in Norcross, Georgia. As of the record date, April 17, 2012, there were 52,699,519 shares of Common Stock entitled to vote at the annual meeting. Represented at the meeting in person or by proxy were 45,798,937 votes representing 86.91 percent of the total shares of Common Stock entitled to vote at the meeting.

The purpose of the meeting was to elect seven directors to a one-year term expiring in 2013, to approve an amendment to the company's certificate of incorporation to increase the number of authorized shares of common stock to a total of 145,000,000 shares, to approve an amendment to the company's 1995 stock plan to increase the number of shares of common stock available for grant by 5,000,000 shares and to ratify the appointment of UHY LLP as the Company's independent registered public accounting firm for the 2012 fiscal year. The following table sets forth the results of the vote on the matters:

PROPOSAL TO ELECT THE DIRECTOR NOMINEES NAMES IN THE COMPANY'S 2012 PROXY 1. STATEMENT.

MARK L FAUPEL PHD	Abstain	19,355,581 3,260,693 1,129,144 22,053,519
RONALD W ALLEN	Against Abstain	
RONALD W HART PHD	Against Abstain	20,065,517 3,240,195 439,706 22,053,519
JOHN E IMHOFF MD		21,629,869 868,157 1,247,392 22,053,519
MICHAEL C JAMES	For Against	19,517,338 3,668,226

Abstain 559,854 Non Votes 22,053,519

JOHNATHAN M NILOFF MD For 22,599,417

Against 564,579 Abstain 581,422 Non Votes 22,053,519

LINDA ROSENSTOCK MD For 22,908,773

Against 399,039 Abstain 437,606 Non Votes 22,053,519

2

TO APPROVE AN AMENDMENT TO THE COMPANY'S CERTIFICATE OF INCORPORATION TO 2. INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK TO A TOTAL OF 145,000,000 SHARES:

For 35,414,020 Against 9,072,072 Abstain 1,312,845

 $_{\rm 3}.$ TO APPROVE AN AMENDMENT TO THE COMPANY'S 1995 STOCK PLAN TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AVAILABLE FOR GRANT BY 5,000,000 SHARES:

For 17,892,935 Against 5,842,788 Abstain 9,695 Non Votes 22,053,519

4. APPROVAL TO RATIFY THE APPOINTMENT OF UHY, LLP AS THE COMPANY'S INDEPENDENT AUDITORS FOR FISCAL 2012:

For 43,199,143 Against 990,648 Abstain 1,609,146

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GUIDED THERAPEUTICS, INC.

By: /s/ Mark L. Faupel, Ph.D. Mark L. Faupel, Ph.D. CEO & President

Date: June 18, 2012

4